SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
MediciNova, Inc. Announces Scheduling of End-of-Phase 2 Meeting With FDA for MN-221 for the Treatment of Acute Exacerbations of Asthma